PR Newswire

Fri Dec 1

First Subject Enrolled in Phase 1 Study of MRX-5

Written by PR Newswire Asia - News Pronto RSS

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceuticals Co., Ltd. (hereinafter referred to as ＂MicuRx＂) announced that its proprietary antibiotic MRX-5, has enrolled its first subject in the first Phase I clinical trial in Australia.

MRX-5 is a new type of benzodiazepine antibiotic used to treat infections...

PR Newswire

First Subject Enrolled in Phase 1 Study of MRX-5

More Articles ...

Game of Thrones Inspired wall divides office workplace

Worried about your drinking during lockdown? These 8 signs might indicate a problem

Here's what needs to happen to get the NDIS back on track

The art of conversation is DEAD

In the Democrats' bitter race to find a candidate to beat Trump, might Elizabeth Warren hold the key?

‘Where are you from?’ is a complicated question. This is how young Australians answer

New South Wales has 48 selective schools, while Victoria has 4. There's an interesting history behind this

Australia's media has been too white for too long. This is how to bring more diversity to newsrooms

Curious Kids: why are our top eyelashes longer than our bottom eyelashes?

Strength from perpetual grief: how Aboriginal people experience the bushfire crisis

Ups and downs of UAE property Market in 2015